- Financing to support research and development pipeline of differentiated drug candidates.
- The agreement is backed by the InvestEU programme, which aims to trigger more than €372 billion in additional investment over the period 2021-27.
- The Danish company’s R&D pipeline includes drug candidates targeting obesity, rare diseases and chronic inflammation.
Danish biotechnology company Zealand Pharma A/S has signed a loan facility of €90 million with the European Investment Bank (EIB), the long-term lending institution of the European Union owned by the Member States. Zealand focuses on the discovery and development of innovative peptide-based medicines, and will use the EIB funding to advance its differentiated research and development pipeline of clinical-stage product candidates targeting obesity, rare diseases and chronic inflammation.
The project is made possible with the support of the InvestEU programme, which aims to mobilise over €372 billion in additional investment for EU policy priorities over the period 2021-2027.